ReviewJournal of cosmetic dermatology2026
TriHex Technology and Reversal of Solar Elastosis: Dispelling Some Myths.
Review in Journal of cosmetic dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSolar elastosis (SE) is the end result of long-term sun damage, characterized by a buildup of dystrophic material in the extracellular matrix (ECM) surrounded by fragmented collagen and dysfunctional, aggregated elastin. This degenerative process was once thought to be irreversible but is now recognized as dynamic, with the potential for regenerative change through appropriate interventions. New stains also enable the detection of newly formed elastin and collagen as part of this reversal process. MATERIALS AND
methodsA retrospective analysis of multiple clinical studies (624 patients, 80 biopsies, 31 reported solar elastosis) was conducted, focusing on the use of TriHex and TriHex+ peptide-based technology (Alastin Skincare Inc., Carlsbad, CA). Biopsies were evaluated using novel histologic stains, including Herovici and Movat, alongside conventional Hematoxylin & Eosin (H&E) and CD44. Markers such as Collagen IV and Laminin at the dermo-epidermal junction (DEJ) were also assessed to identify evidence of regenerative reversal of solar elastosis, ECM remodeling, and new elastin formation.
resultsThe regenerative reversal of solar elastosis was observed across multiple clinical trials. The TriHex formulations consistently produced significant improvements in ECM structure. Reported histology in 74% of cases showed clear removal of amorphous elastotic deposits and restoration of the ECM, including new elastin fiber formation, strengthening of the DEJ with increased Collagen IV and Laminin, new rete ridge architecture, and positive hydration effects evidenced by increased CD44 staining.
conclusionThis review positively challenges a long-standing myth and clearly establishes a new perspective: solar elastosis is reversible. The peptide-based TriHex Technology can remove the elastotic amorphous material from the ECM and rebuild it with new elastin and collagen fibers. Clinically and histologically, this shows that chronic sun damage can be repaired in the dermis, supporting a shift from superficial treatments to a more targeted regenerative approach focused on restoring the structural integrity of the skin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.